R1	Has_value Arg1:T2 Arg2:T1	
*	OR T9 T10
R2	Has_temporal Arg1:T14 Arg2:T13	
R3	Has_multiplier Arg1:T14 Arg2:T12	
R4	multi Arg1:T11 Arg2:T14	
R5	Has_temporal Arg1:T9 Arg2:T11	
R6	Has_qualifier Arg1:T8 Arg2:T9	
R7	Has_temporal Arg1:T21 Arg2:T20	
R8	Has_temporal Arg1:T17 Arg2:T18	
*	OR T16 T17
R9	causal Arg1:T16 Arg2:T21	
R10	Has_qualifier Arg1:T22 Arg2:T23	
R11	Has_qualifier Arg1:T22 Arg2:T24	
R12	Has_value Arg1:T27 Arg2:T26	
R13	Has_qualifier Arg1:T22 Arg2:T28	
R14	Has_temporal Arg1:T29 Arg2:T30	
R15	causal Arg1:T22 Arg2:T29	
R16	multi Arg1:T28 Arg2:T27	
R17	Has_temporal Arg1:T32 Arg2:T33	
R18	multi Arg1:T31 Arg2:T35	
R19	multi Arg1:T35 Arg2:T34	
R20	Has_mood Arg1:T40 Arg2:T41	
R21	AND Arg1:T39 Arg2:T40	
R22	Has_qualifier Arg1:T39 Arg2:T37	
R23	multi Arg1:T44 Arg2:T45	
R24	Has_qualifier Arg1:T46 Arg2:T43	
R25	Has_qualifier Arg1:T46 Arg2:T44	
R26	causal Arg1:T46 Arg2:T47	
R27	Has_qualifier Arg1:T46 Arg2:T42	
R28	Has_temporal Arg1:T36 Arg2:T48	
R29	causal Arg1:T34 Arg2:T32	
R30	causal Arg1:T36 Arg2:T32	
R31	causal Arg1:T39 Arg2:T34	
*	OR T34 T36 T39 T46
R32	multi Arg1:T54 Arg2:T55	
R33	Has_temporal Arg1:T53 Arg2:T54	
R34	multi Arg1:T57 Arg2:T59	
R35	multi Arg1:T58 Arg2:T59	
R36	Has_temporal Arg1:T56 Arg2:T57	
*	OR T64 T65 T66
*	OR T62 T63
R37	multi Arg1:T62 Arg2:T67	
R38	multi Arg1:T67 Arg2:T61	
R39	Has_negation Arg1:T64 Arg2:T68	
R40	AND Arg1:T62 Arg2:T64	
*	OR T72 T73
R41	Has_qualifier Arg1:T71 Arg2:T72	
R42	Has_mood Arg1:T79 Arg2:T77	
R43	AND Arg1:T78 Arg2:T79	
*	OR T75 T78 T76
R44	Has_mood Arg1:T82 Arg2:T81	
R45	AND Arg1:T83 Arg2:T82	
R46	Has_qualifier Arg1:T85 Arg2:T86	
R47	Has_temporal Arg1:T85 Arg2:T87	
R48	Has_value Arg1:T89 Arg2:T90	
R49	multi Arg1:T88 Arg2:T89	
*	OR T91 T92
R50	Has_temporal Arg1:T94 Arg2:T95	
R51	Has_temporal Arg1:T91 Arg2:T93	
*	OR T91 T94
R52	Has_temporal Arg1:T97 Arg2:T98	
R53	Has_qualifier Arg1:T99 Arg2:T100	
R54	Has_qualifier Arg1:T99 Arg2:T101	
R55	Has_negation Arg1:T99 Arg2:T102	
R56	AND Arg1:T97 Arg2:T99	
R57	Has_temporal Arg1:T56 Arg2:T58	
T1	Value 12 36	over the age of 85 years
T2	Person 21 24	age
T3	Subjective_judgement 44 81	at the discretion of the Investigator
T4	Post-eligibility 3 116	Patients over the age of 85 years except at the discretion of the Investigator and with agreement of the Sponsor.
T5	Condition 134 162	acute promyelocytic leukemia
T6	Condition 180 214	chronic myelogenous leukemia (CML)
T7	Condition 218 230	blast crisis
T8	Condition 235 238	AML
T9	Qualifier 239 249	in relapse
T10	Qualifier 253 263	refractory
T11	Temporal 264 310	after 3 or more previous lines of chemotherapy
T12	Multiplier 270 279	3 or more
T13	Temporal 280 288	previous
T14	Procedure 289 310	lines of chemotherapy
T16	Condition 339 342	AML
T17	Condition 357 360	MDS
T18	Temporal 346 356	antecedent
T20	Temporal 374 379	prior
T21	Condition 380 392	chemotherapy
T22	Condition 449 457	toxicity
T23	Qualifier 431 448	non-hematological
T24	Qualifier 408 430	clinically significant
T25	Subjective_judgement 408 430	clinically significant
T26	Value 466 474	Grade >1
T27	Measurement 478 490	NCI CTCAE v4
T28	Qualifier 466 490	Grade >1 by NCI CTCAE v4
T29	Procedure 502 514	chemotherapy
T30	Temporal 496 501	prior
T31	Temporal 554 583	within 100 days of transplant
T32	Condition 541 545	HSCT
T33	Temporal 532 540	have had
T34	Procedure 573 583	transplant
T35	Reference_point 573 583	transplant
T36	Drug 608 631	immunosuppressive drugs
T37	Qualifier 644 666	clinically significant
T38	Subjective_judgement 644 666	clinically significant
T39	Condition 667 692	graft-versus-host disease
T40	Procedure 703 712	treatment
T41	Mood 693 702	requiring
T42	Qualifier 725 733	>Grade 1
T43	Qualifier 745 762	non hematological
T44	Qualifier 734 744	persistent
T45	Multiplier 734 744	persistent
T46	Condition 763 771	toxicity
T47	Procedure 787 797	transplant
T48	Temporal 595 600	still
T49	Condition 820 857	central nervous system (CNS) leukemia
T50	Non-representable 859 1093	Patients with CNS leukemia, which is controlled, but who are still receiving IT therapy at study entry may be considered eligible and continue receive IT therapy at the discretion of the Investigator and with agreement of the Sponsor.
T51	Drug 1136 1141	AC220
T52	Condition 1147 1191	Disseminated intravascular coagulation (DIC)
T53	Procedure 1246 1259	Major surgery
T54	Temporal 1260 1294	within 4 weeks prior to enrollment
T55	Reference_point 1284 1294	enrollment
T56	Procedure 1313 1330	Radiation therapy
T57	Temporal 1331 1354;1375 1380	within 4 weeks prior to study
T58	Temporal 1359 1380	concurrent with study
T59	Reference_point 1375 1380	study
T61	Condition 1416 1439	prolong QT/QTc interval
T62	Drug 1405 1439	drugs that prolong QT/QTc interval
T63	Drug 1451 1468	CYP3A4 inhibitors
T64	Drug 1506 1517	antibiotics
T65	Drug 1519 1530	antifungals
T66	Drug 1542 1556	antimicrobials
T67	Qualifier 1411 1439	that prolong QT/QTc interval
T68	Negation 1484 1505	with the exception of
T71	Condition 1746 1768	cardiovascular disease
T72	Qualifier 1718 1730	Uncontrolled
T73	Qualifier 1734 1745	significant
T75	Condition 1788 1796	pregnant
T76	Condition 1798 1807	lactating
T77	Mood 1812 1821	unwilling
T78	Condition 1849 1871	childbearing potential
T79	Condition 1829 1842	contraception
T80	Person 1877 1880	Men
T81	Mood 1889 1898	unwilling
T82	Drug 1906 1919	contraception
T83	Observation 1923 1967	their partners are of childbearing potential
T84	Non-representable 1923 1967	their partners are of childbearing potential
T85	Condition 1994 2003	infection
T86	Qualifier 1981 1993	uncontrolled
T87	Temporal 1973 1979	Active
T88	Condition 2009 2037	Human immunodeficiency virus
T89	Measurement 2009 2037	Human immunodeficiency virus
T90	Value 2038 2048	positivity
T91	Condition 2061 2072	hepatitis B
T92	Condition 2061 2070;2076 2077	hepatitis C
T93	Temporal 2054 2060	Active
T94	Condition 2094 2107	liver disease
T95	Temporal 2087 2093	active
T97	Condition 2124 2130	cancer
T98	Temporal 2113 2120	History
T99	Condition 2170 2181	skin cancer
T100	Qualifier 2157 2169	nonmelanotic
T101	Qualifier 2139 2153	Stage 1 cervix
T102	Negation 2132 2138	except
